[Joint manifestations related to Clostridium difficile].
BACKGROUND
Reactional joint disease subsequent to digestive tract infections have been well studied for Salmonella, Shigella, Yersinia and Campylobacter. Association with HLA B27 is well documented. A review of the literature since 1976 disclosed 23 cases of articular and extra-articular inflammatory reactions following pseudomembranous Clostridium difficile infection.


METHODS
We describe 2 new cases which followed a favorable course. This is the usual outcome although inflammatory manifestations may persist or relapse.


CONCLUSIONS
The pathophysiological interest of this condition lies in the pathogenic potential of Clostridium difficile which appears to be directly related to toxin production. This would suggest an immune mechanism rather than pure infection.
Vermeulen
C
C
Hôpital Lariboisière, Paris.
Lemaire
V
V
Lioté
F
F
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000188:drug therapy / Q000209:etiology*; D016360:Clostridioides difficile / Q000302:isolation & purification; D004008:Diclofenac / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004761:Enterocolitis, Pseudomembranous / Q000150:complications* / Q000175:diagnosis; D005243:Feces / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007660:Ketoprofen / Q000627:therapeutic use; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D008795:Metronidazole; D004008:Diclofenac; D019980:Amoxicillin-Potassium Clavulanate Combination; D000583:Amikacin; D007660:Ketoprofen